TTM
$12.45B
YoY change
+31.5%
5Y CAGR
+23.1%
Peak year (2025)
$12.70B
Cumulative operating income
$192.10B
Operating Income history chart for Bristol-Myers Squibb (BMY) from 1987 to 2025
Latest: $12.70B
Operating Income growth chart for Bristol-Myers Squibb (BMY) from 1987 to 2025
Latest: +31.5%
Operating Income history table for Bristol-Myers Squibb (BMY) from 1987 to 2025
| 2025 | $12.70B | +31.5% | +$3.04B | ||
| 2024 | $9.66B | +14.0% | +$1.19B | ||
| 2023 | $8.47B | -8.6% | −$799.00M | ||
| 2022 | $9.27B | -2.8% | −$269.00M | ||
| 2021 | $9.54B | +112.4% | +$5.05B | ||
| 2020 | $4.49B | -30.2% | −$1.95B | ||
| 2019 | $6.44B | +0.7% | +$45.00M | ||
| 2018 | $6.39B | +22.0% | +$1.16B | ||
| 2017 | $5.24B | +1.2% | +$60.00M | ||
| 2016 | $5.18B | +31.5% | +$1.24B | ||
| 2015 | $3.94B | +25.6% | +$803.00M | ||
| 2014 | $3.13B | +0.2% | +$5.00M | ||
| 2013 | $3.13B | -26.6% | −$1.14B | ||
| 2012 | $4.27B | -36.8% | −$2.48B | ||
| 2011 | $6.75B | +10.0% | +$615.00M | ||
| 2010 | $6.14B | +21.6% | +$1.09B | ||
| 2009 | $5.05B | +3.5% | +$173.00M | ||
| 2008 | $4.88B | +29.4% | +$1.11B | ||
| 2007 | $3.77B | +42.6% | +$1.13B | ||
| 2006 | $2.64B | -36.0% | −$1.48B | ||
| 2005 | $4.13B | -12.2% | −$574.00M | ||
| 2004 | $4.70B | -4.7% | −$234.00M | ||
| 2003 | $4.93B | +20.3% | +$832.00M | ||
| 2002 | $4.10B | -20.5% | −$1.06B | ||
| 2001 | $5.16B | -13.8% | −$828.00M | ||
| 2000 | $5.99B | +14.3% | +$747.00M | ||
| 1999 | $5.24B | +17.6% | +$783.00M | ||
| 1998 | $4.46B | +0.4% | +$18.00M | ||
| 1997 | $4.44B | +12.3% | +$485.00M | ||
| 1996 | $3.95B | +9.3% | +$338.00M | ||
| 1995 | $3.62B | +12.2% | +$394.00M | ||
| 1994 | $3.22B | +34.0% | +$818.00M | ||
| 1993 | $2.40B | +22.6% | +$443.00M | ||
| 1992 | $1.96B | -29.1% | −$806.00M | ||
| 1991 | $2.77B | +15.8% | +$377.00M | ||
| 1990 | $2.39B | +120.6% | +$1.31B | ||
| 1989 | $1.08B | -38.8% | −$687.00M | ||
| 1988 | $1.77B | +20.7% | +$303.00M | ||
| 1987 | $1.47B | — | — |
- 2025$12.70B+31.5%
- 2024$9.66B+14.0%
- 2023$8.47B-8.6%
- 2022$9.27B-2.8%
- 2021$9.54B+112.4%
- 2020$4.49B-30.2%
- 2019$6.44B+0.7%
- 2018$6.39B+22.0%
- 2017$5.24B+1.2%
- 2016$5.18B+31.5%
- 2015$3.94B+25.6%
- 2014$3.13B+0.2%
- 2013$3.13B-26.6%
- 2012$4.27B-36.8%
- 2011$6.75B+10.0%
- 2010$6.14B+21.6%
- 2009$5.05B+3.5%
- 2008$4.88B+29.4%
- 2007$3.77B+42.6%
- 2006$2.64B-36.0%
- 2005$4.13B-12.2%
- 2004$4.70B-4.7%
- 2003$4.93B+20.3%
- 2002$4.10B-20.5%
- 2001$5.16B-13.8%
- 2000$5.99B+14.3%
- 1999$5.24B+17.6%
- 1998$4.46B+0.4%
- 1997$4.44B+12.3%
- 1996$3.95B+9.3%
- 1995$3.62B+12.2%
- 1994$3.22B+34.0%
- 1993$2.40B+22.6%
- 1992$1.96B-29.1%
- 1991$2.77B+15.8%
- 1990$2.39B+120.6%
- 1989$1.08B-38.8%
- 1988$1.77B+20.7%
- 1987$1.47B—
Operating Income values are taken from Bristol-Myers Squibb's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Bristol-Myers Squibb (BMY)
According to Bristol-Myers Squibb's latest reported financial statements, the company's current operating income (TTM) is $12.45B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Bristol-Myers Squibb (BMY) reported operating income of $12.70B – surged 31.5% year-over-year.
Across 2020–2025 (5 years), Bristol-Myers Squibb operating income produced a CAGR of +23.1% – sustaining 2 straight years of year-over-year growth.
The highest annual operating income of $12.70B was reported in 2025. The lowest in the available history was $1.08B in 1989.
Bristol-Myers Squibb Operating Income by Year
Bristol-Myers Squibb Operating Income 2025: $12.70B
Bristol-Myers Squibb operating income in 2025 was $12.70B, surged 31.5% from 2024. This figure represents the highest annual value in the available history.
Bristol-Myers Squibb Operating Income 2024: $9.66B
2024's operating income for Bristol-Myers Squibb came in at $9.66B, grew 14.0% from 2023.
Bristol-Myers Squibb Operating Income 2023: $8.47B
Bristol-Myers Squibb posted operating income of $8.47B in 2023, declined 8.6% below 2022.
Bristol-Myers Squibb Operating Income 2022: $9.27B
In 2022, Bristol-Myers Squibb reported operating income of $9.27B, edged down 2.8% below 2021.
Bristol-Myers Squibb Operating Income 2021: $9.54B
Bristol-Myers Squibb operating income in 2021 was $9.54B.
See more financial history for Bristol-Myers Squibb (BMY).
Sector peers by Operating Income
Healthcare peers of Bristol-Myers Squibb (BMY), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation